The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Nov. 17, 2021
Applicant:

Applied Molecular Transport Inc., South San Francisco, CA (US);

Inventors:

Randall J. Mrsny, Los Altos Hills, CA (US);

Tahir Mahmood, Burlingame, CA (US);

Amir Porat, Belmont, CA (US);

Charles Olson, South San Francisco, CA (US);

Sally Postlethwaite, Redwood City, CA (US);

Weijun Feng, Danville, CA (US);

Khushdeep Mangat, Cambridge, MA (US);

Assignee:

Applied Molecular Transport Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/54 (2006.01); C07K 1/14 (2006.01); C07K 1/18 (2006.01); C07K 1/34 (2006.01); C07K 1/36 (2006.01); C07K 14/28 (2006.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/5428 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); C07K 1/145 (2013.01); C07K 1/18 (2013.01); C07K 1/34 (2013.01); C07K 1/36 (2013.01); C07K 14/28 (2013.01); A61K 38/00 (2013.01);
Abstract

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in theof the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.


Find Patent Forward Citations

Loading…